Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722384 · ClinicalTrials.gov registry record · Phase 1
Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5
A Phase 1 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00722384 is a Phase 1 study that has completed, run by OPKO Health. The registered enrollment target is 15 participants.
The verdict
NCT00722384, a Phase 1 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal injection in patients with wet age-related macular degeneration.
Interventions
- DRUG bevasiranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722384
The ClinicalTrials.gov registry entry for NCT00722384 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bevasiranib is the first listed.
NCT00722384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00722384 about?
NCT00722384 is a clinical study titled "Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5". To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal injection in patients with wet age-related macular degeneration.
What is the current status of trial NCT00722384?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2004-08. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00722384?
The interventions under investigation include: bevasiranib (DRUG).
Who is sponsoring clinical trial NCT00722384?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.